coumarin has been researched along with Extensively Drug-Resistant Tuberculosis in 1 studies
2H-chromen-2-one: coumarin derivative
Extensively Drug-Resistant Tuberculosis: Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reddy, DS | 1 |
| Kongot, M | 1 |
| Kumar, A | 1 |
1 review available for coumarin and Extensively Drug-Resistant Tuberculosis
| Article | Year |
|---|---|
Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Coumarins; Drug Design; Drug Resistance, Bacterial; Extensively Drug | 2021 |